220 related articles for article (PubMed ID: 31725935)
1. Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment.
Blazevski A; Scheltema MJ; Amin A; Thompson JE; Lawrentschuk N; Stricker PD
BJU Int; 2020 Mar; 125(3):369-378. PubMed ID: 31725935
[TBL] [Abstract][Full Text] [Related]
2. Focal irreversible electroporation as primary treatment for localized prostate cancer.
van den Bos W; Scheltema MJ; Siriwardana AR; Kalsbeek AMF; Thompson JE; Ting F; Böhm M; Haynes AM; Shnier R; Delprado W; Stricker PD
BJU Int; 2018 May; 121(5):716-724. PubMed ID: 28796935
[TBL] [Abstract][Full Text] [Related]
3. The safety and efficacy of irreversible electroporation for the ablation of prostate cancer: a multicentre prospective human in vivo pilot study protocol.
van den Bos W; de Bruin DM; Muller BG; Varkarakis IM; Karagiannis AA; Zondervan PJ; Laguna Pes MP; Veelo DP; Savci Heijink CD; Engelbrecht MRW; Wijkstra H; de Reijke TM; de la Rosette JJMCH
BMJ Open; 2014 Oct; 4(10):e006382. PubMed ID: 25354827
[TBL] [Abstract][Full Text] [Related]
4. Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial.
Scheltema MJ; van den Bos W; de Bruin DM; Wijkstra H; Laguna MP; de Reijke TM; de la Rosette JJ
BMC Cancer; 2016 May; 16():299. PubMed ID: 27150293
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer.
Scheltema MJ; van den Bos W; Siriwardana AR; Kalsbeek AMF; Thompson JE; Ting F; Böhm M; Haynes AM; Shnier R; Delprado W; Stricker PD
BJU Int; 2017 Nov; 120 Suppl 3():51-58. PubMed ID: 28834167
[TBL] [Abstract][Full Text] [Related]
6. A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT).
Valerio M; Dickinson L; Ali A; Ramachandran N; Donaldson I; Freeman A; Ahmed HU; Emberton M
Contemp Clin Trials; 2014 Sep; 39(1):57-65. PubMed ID: 25072507
[TBL] [Abstract][Full Text] [Related]
7. Effect of Focal vs Extended Irreversible Electroporation for the Ablation of Localized Low- or Intermediate-Risk Prostate Cancer on Early Oncological Control: A Randomized Clinical Trial.
Zhang K; Teoh J; Laguna P; Dominguez-Escrig J; Barret E; Ramon-Borja JC; Muir G; Bohr J; de Reijke TM; Pelechano Gómez P; Ng CF; Sanchez-Salas R; de la Rosette J
JAMA Surg; 2023 Apr; 158(4):343-349. PubMed ID: 36723911
[TBL] [Abstract][Full Text] [Related]
8. A prospective Phase 2a pilot study investigating focal percutaneous irreversible electroporation (IRE) ablation by NanoKnife in patients with localised renal cell carcinoma (RCC) with delayed interval tumour resection (IRENE trial).
Wendler JJ; Porsch M; Nitschke S; Köllermann J; Siedentopf S; Pech M; Fischbach F; Ricke J; Schostak M; Liehr UB
Contemp Clin Trials; 2015 Jul; 43():10-9. PubMed ID: 25962890
[TBL] [Abstract][Full Text] [Related]
9. [Irreversible electroporation. Current value for focal treatment of prostate cancer].
Wendler JJ; Ganzer R; Hadaschik B; Blana A; Henkel T; Köhrmann KU; Machtens S; Roosen A; Salomon G; Sentker L; Witzsch U; Schlemmer HP; Baumunk D; Köllermann J; Schostak M; Liehr UB;
Urologe A; 2015 Jun; 54(6):854-62. PubMed ID: 26024649
[TBL] [Abstract][Full Text] [Related]
10. Percutaneous irreversible electroporation (IRE) of prostate cancer: Contrast-enhanced ultrasound (CEUS) findings during follow up.
Beyer LP; Pregler B; Nießen C; Michalik K; Haimerl M; Stroszczynski C; Jung EM; Wiggermann P
Clin Hemorheol Microcirc; 2016; 64(3):501-506. PubMed ID: 27935553
[TBL] [Abstract][Full Text] [Related]
11. Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy.
Scheltema MJ; Chang JI; Böhm M; van den Bos W; Blazevski A; Gielchinsky I; Kalsbeek AMF; van Leeuwen PJ; Nguyen TV; de Reijke TM; Siriwardana AR; Thompson JE; de la Rosette JJ; Stricker PD
World J Urol; 2018 Sep; 36(9):1383-1389. PubMed ID: 29594551
[TBL] [Abstract][Full Text] [Related]
12. Why we should not routinely apply irreversible electroporation as an alternative curative treatment modality for localized prostate cancer at this stage.
Wendler JJ; Ganzer R; Hadaschik B; Blana A; Henkel T; Köhrmann KU; Machtens S; Roosen A; Salomon G; Sentker L; Witzsch U; Schlemmer HP; Baumunk D; Köllermann J; Schostak M; Liehr UB
World J Urol; 2017 Jan; 35(1):11-20. PubMed ID: 27147512
[TBL] [Abstract][Full Text] [Related]
13. Median 4-year outcomes of salvage irreversible electroporation for localized radio-recurrent prostate cancer.
Geboers B; Scheltema MJ; Blazevski A; Katelaris A; Doan P; Ali I; Agrawal S; Barreto D; Matthews J; Haynes AM; Delprado W; Shnier R; Thompson JE; Stricker PD
BJU Int; 2023 Jun; 131 Suppl 4():14-22. PubMed ID: 36594205
[TBL] [Abstract][Full Text] [Related]
14. Focal Therapy of Prostate Cancer Using Irreversible Electroporation.
Valerio M; Ahmed HU; Emberton M
Tech Vasc Interv Radiol; 2015 Sep; 18(3):147-52. PubMed ID: 26365544
[TBL] [Abstract][Full Text] [Related]
15. The correlation between the electrode configuration and histopathology of irreversible electroporation ablations in prostate cancer patients.
van den Bos W; de Bruin DM; Jurhill RR; Savci-Heijink CD; Muller BG; Varkarakis IM; Skolarikos A; Zondervan PJ; Laguna-Pes MP; Wijkstra H; de Reijke TM; de la Rosette JJ
World J Urol; 2016 May; 34(5):657-64. PubMed ID: 26296371
[TBL] [Abstract][Full Text] [Related]
16. Pilot Study to Assess Safety and Clinical Outcomes of Irreversible Electroporation for Partial Gland Ablation in Men with Prostate Cancer.
Murray KS; Ehdaie B; Musser J; Mashni J; Srimathveeravalli G; Durack JC; Solomon SB; Coleman JA
J Urol; 2016 Sep; 196(3):883-90. PubMed ID: 27113966
[TBL] [Abstract][Full Text] [Related]
17. Irreversible electroporation for the treatment of localized prostate cancer: a summary of imaging findings and treatment feedback.
Scheltema MJ; Postema AW; de Bruin DM; Buijs M; Engelbrecht MR; Laguna MP; Wijkstra H; de Reijke TM; de la Rosette JJMCH
Diagn Interv Radiol; 2017; 23(5):365-370. PubMed ID: 28830850
[TBL] [Abstract][Full Text] [Related]
18. New and Established Technology in Focal Ablation of the Prostate: A Systematic Review.
Valerio M; Cerantola Y; Eggener SE; Lepor H; Polascik TJ; Villers A; Emberton M
Eur Urol; 2017 Jan; 71(1):17-34. PubMed ID: 27595377
[TBL] [Abstract][Full Text] [Related]
19. Irreversible electroporation as a focal therapy for localized prostate cancer: A systematic review.
Prabhakar P; Avudaiappan AP; Sandman M; Eldefrawy A; Caso J; Narayanan G; Manoharan M
Indian J Urol; 2024; 40(1):6-16. PubMed ID: 38314081
[TBL] [Abstract][Full Text] [Related]
20. Nanoknife Electroporation Ablation Trial: A Prospective Development Study Investigating Focal Irreversible Electroporation for Localized Prostate Cancer.
Valerio M; Dickinson L; Ali A; Ramachadran N; Donaldson I; Mccartan N; Freeman A; Ahmed HU; Emberton M
J Urol; 2017 Mar; 197(3 Pt 1):647-654. PubMed ID: 27697580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
